Japan • • JA | To the general public and patients To medical personnel AbbVie Global menu Tomorrow that will lead to a smile together. Click here for details Press Press Release / November 26,2021 AbbVie launches 150 mg / mL prefilled syringe and pen-type formulation , new dosage form of Skillige® in Japan AbbVie launches 30 mg tablet, new dosage form of Lynvoc® in Japan To the list of press releases Notification AbbVie certified as "Best Companies to Work For" attempt Released a video "Museum to watch and listen carefully" that introduces the award-winning works of the Autoimmune Disease Art Project by reading aloud. attempt Autoimmune disease art project attempt Talk Over RA Awareness Website for Rheumatoid Arthritis Patients Established attempt Disease information site "New conversation for atopic dermatitis" opened attempt Efforts to eradicate hepatitis C About us AbbVie is a global R & D-based biopharmacy company headquartered in the United States. Click here for details Science AbbVie's innovations are backed by outstanding science and are created to tackle the most needed challenges. Click here for details Japanese development pipeline We are working in the areas of immune disorders, viruses, cancers and neurological disorders. Disease areas that provide pharmaceutical products We are active in autoimmune diseases such as rheumatoid arthritis, hepatitis C, Parkinson's disease, blood cancer and others. Recruitment information As a new leader in the pharmaceutical industry, why not work together to create a more attractive company? Corporate responsibility At AbbVie, "how to do" is as important as "what to do". We will utilize all resources not only to provide medicines but also to improve medical care and contribute to the local community. Click here for details Video content list inquiry Follow us on Instagram site map privacy policy terms of service Cookie settings Copyright © 2021 AbbVie GK.